Cargando…
Development of Novel Micro-dystrophins with Enhanced Functionality
Gene therapies using adeno-associated viral (AAV) vectors have advanced into clinical trials for several diseases, including Duchenne muscular dystrophy (DMD). A limitation of AAV is the carrying capacity (∼5 kb) available for genes and regulatory cassettes (RCs). These size constraints are problema...
Autores principales: | Ramos, Julian N., Hollinger, Katrin, Bengtsson, Niclas E., Allen, James M., Hauschka, Stephen D., Chamberlain, Jeffrey S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403485/ https://www.ncbi.nlm.nih.gov/pubmed/30718090 http://dx.doi.org/10.1016/j.ymthe.2019.01.002 |
Ejemplares similares
-
Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
por: Bengtsson, Niclas E., et al.
Publicado: (2017) -
Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
por: Bengtsson, Niclas E., et al.
Publicado: (2017) -
The Polyproline Site in Hinge 2 Influences the Functional Capacity of Truncated Dystrophins
por: Banks, Glen B., et al.
Publicado: (2010) -
Micro-dystrophin Gene Therapy Partially Enhances Exercise Capacity in Older Adult mdx Mice
por: Rodgers, Buel D., et al.
Publicado: (2019) -
Assembly of the Dystrophin-Associated Protein Complex Does Not Require the Dystrophin Cooh-Terminal Domain
por: Crawford, Gregory E., et al.
Publicado: (2000)